Payment overview · 2025
General Payments
$1,609.52
52 reported records · 14 companies
Healthcare provider profile · identity verified
Juan C Velazquez, MD
Allopathic & Osteopathic Physicians|Family Medicine · BRAWLEY, CA · NPI 1497812895
Verified facts
What the public records show
CMS Open Payments records show Juan C Velazquez, MD received $1,609.52 in general payments during 2025 across 52 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $396.28 | 24.6% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $348.29 | 21.6% | 11 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $267.48 | 16.6% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $167.55 | 10.4% | 6 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $84.65 | 5.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $64.61 | 4.0% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $60.18 | 3.7% | 3 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $56.29 | 3.5% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.52 | 2.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.86 | 1.9% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $27.69 | 1.7% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $24.10 | 1.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.86 | 1.4% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $14.16 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,609.52 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $267.48 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $217.84 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $213.57 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $167.55 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $136.77 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $134.51 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $84.65 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $64.61 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $64.61 | 2 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $56.29 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.86 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $30.86 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $27.69 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 70 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | 32 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
17 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 391 | 197 |
| Metformin Hcl | Metformin Hcl | 347 | 163 |
| Gabapentin | Gabapentin | 336 | 171 |
| Amlodipine Besylate | Amlodipine Besylate | 283 | 132 |
| Losartan Potassium | Losartan Potassium | 278 | 133 |
| Omeprazole | Omeprazole | 233 | 114 |
| Alendronate Sodium | Alendronate Sodium | 227 | 94 |
| Lisinopril | Lisinopril | 205 | 82 |
| Meloxicam | Meloxicam | 182 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 175 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 80 |
| Ibuprofen | Ibuprofen | 129 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 54 |
| Baclofen | Baclofen | 112 | 64 |
| Fenofibrate | Fenofibrate Nanocrystallized | 102 | 50 |
| Glimepiride | Glimepiride | 100 | 49 |
| Furosemide | Furosemide | 97 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 49 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 50 |
| Meclizine Hcl | Meclizine Hcl | 81 | 55 |
| Ozempic | Semaglutide | 80 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 28 |
| Farxiga | Dapagliflozin Propanediol | 70 | 32 |
| Trazodone Hcl | Trazodone Hcl | 70 | 34 |
| Azithromycin | Azithromycin | 69 | 64 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 68 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 36 |
| Potassium Chloride | Potassium Chloride | 66 | 28 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 62 | 60 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 60 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 27 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 52 | 17 |
| Clonidine Hcl | Clonidine Hcl | 51 | 22 |
| Naproxen | Naproxen | 50 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 47 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 32 |
| Carvedilol | Carvedilol | 46 | 25 |
| Simvastatin | Simvastatin | 46 | 24 |
| Nifedipine Er | Nifedipine | 45 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 39 |
| Allopurinol | Allopurinol | 43 | 24 |
| Prednisone | Prednisone | 43 | 40 |
| Finasteride | Finasteride | 42 | 28 |
| Ketoconazole | Ketoconazole | 42 | 22 |
| Trulicity | Dulaglutide | 41 | 13 |
| Januvia | Sitagliptin Phosphate | 39 | 19 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 34 |
| Enalapril Maleate | Enalapril Maleate | 36 | 12 |
| Jardiance | Empagliflozin | 34 | 14 |
| Tradjenta | Linagliptin | 34 | 15 |
| Tramadol Hcl | Tramadol Hcl | 34 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 20 |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 30 | 17 |
| Diclofenac Potassium | Diclofenac Potassium | 30 | 21 |
| Icosapent Ethyl | Icosapent Ethyl | 30 | 17 |
| Sertraline Hcl | Sertraline Hcl | 30 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 28 | 18 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 28 | 25 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | 12 |
| Sucralfate | Sucralfate | 25 | 16 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 12 |
| Linzess | Linaclotide | 23 | 14 |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | 14 |
| Rybelsus | Semaglutide | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | 13 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | 18 |
| Metronidazole | Metronidazole | 18 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Eliquis | Apixaban | 17 | 12 |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | 12 |
| Saxagliptin Hcl | Saxagliptin Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 11 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,609.52 · 52 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, APTIMA, AREXVY, BREZTRI, COLLAGENASE SANTYL, FARXIGA, Kerendia, NURTEC ODT, Ozempic, QUTENZA, REZDIFFRA, SHINGRIX, Wegovy, XIFAXAN, ZAVZPRET, t:slim X2 Insulin Pump with Control-IQ | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error